News
TNXP
13.90
-3.10%
-0.45
Tonix Pharmaceuticals publishes Tonmya study data findings
TipRanks · 1d ago
Tonix Pharmaceuticals Announces Publication Of The Paper "Steady-State Pharmacokinetic Properties Of TNX-102 SL, A Sublingual Tablet Formulation Of Cyclobenzaprine Hydrochloride (HCl), With Daily Dosing In Healthy Volunteers: A Randomized, Open-label Trial," In The Journal 'Clinical Pharmacology In Drug Development'
Benzinga · 1d ago
Tonix publishes Day 20 steady-state PK study of TONMYA in clinical journal
PUBT · 1d ago
Analysts Are Bullish on These Healthcare Stocks: Delcath Systems (DCTH), Tonix Pharma (TNXP)
TipRanks · 3d ago
Weekly Report: what happened at TNXP last week (0406-0410)?
Weekly Report · 3d ago
Tonix publishes investor deck highlighting TONMYA fibromyalgia launch, reports USD 208 million cash
Reuters · 04/07 18:48
Analysts Offer Insights on Healthcare Companies: Privia Health Group (PRVA), Nuvalent (NUVL) and Tonix Pharma (TNXP)
TipRanks · 04/06 11:40
Weekly Report: what happened at TNXP last week (0330-0403)?
Weekly Report · 04/06 09:12
Insiders Shake Up Vale, Gevo, Macy’s, Tonix, Southern
TipRanks · 04/04 13:00
Tonix Pharma CEO Makes Bold Insider Move Amid Market Uncertainty
TipRanks · 04/02 02:03
Tonix CEO Seth Lederman buys TNXP shares worth $0.1 million
Reuters · 04/01 13:31
Tonix publishes investor presentation highlighting TONMYA fibromyalgia launch and early sales traction
Reuters · 04/01 13:29
Tonix publishes presentation on long-acting monoclonal antibody to prevent Lyme disease
Reuters · 03/31 22:25
Tonix publishes investor presentation highlighting TONMYA fibromyalgia drug launch progress
Reuters · 03/31 21:48
Tonix plans adaptive Phase 2 field trial of TNX-4800 for Lyme prevention in 2027
Reuters · 03/31 21:18
Tonix publishes TNX-4800 long-acting monoclonal antibody presentation for Lyme disease prevention
Reuters · 03/31 21:06
Tonix Pharma Advances TNX-4800 Lyme Disease Prevention Program
TipRanks · 03/31 14:45
Tonix Pharmaceuticals presents TNX-4800 data, to initiate adaptive field study
TipRanks · 03/31 11:25
Tonix Pharmaceuticals Says Phase 1 Data of TNX-4800 (mAb 2217LS) For Preventing Lyme Disease Demonstrated Safety, Tolerability, And Pharmacokinetics Supportive Of Approximately Four Months Protection
Benzinga · 03/31 11:10
TONIX PHARMACEUTICALS ANNOUNCES PRESENTATION OF PHASE 1 DATA AND OUTLINES PLANNED ADAPTIVE PHASE 2 FIELD STUDY OF TNX-4800 FOR THE PREVENTION OF LYME DISEASE, AT THE WORLD VACCINE CONGRESS WASHINGTON 2026
Reuters · 03/31 11:00
More
Webull provides a variety of real-time TNXP stock news. You can receive the latest news about Tonix Pharmaceut through multiple platforms. This information may help you make smarter investment decisions.
About TNXP
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapeutics to treat and vaccines to prevent, disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801, TNX-1800, TNX-4200, and TNX-1700. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.